PRL-1 Engineered Mesenchymal Stem Cell Composition to Inhibit Adipogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for adipogenesis and fat accumulation are inadequate, lacking effective and safe methods to fundamentally address these issues.
Innovation Solution
The use of mesenchymal stem cells engineered to overexpress phosphatase of regenerating liver-1 (PRL-1) to inhibit adipogenesis and fat accumulation, which can be administered or used in health functional foods to treat diseases associated with abnormal adipogenesis or abnormal fat metabolic dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary therapy or drug therapy is used to treat fat accumulation, then treatment of symptoms can be achieved, but fundamental treatment of adipogenesis is not possible
Solution Approach 1:
The patent introduces mesenchymal stem cells as an intermediary therapeutic agent that mediates the inhibition of adipogenesis. These stem cells act as a biological mediator between the treatment administration and the target adipose tissue, fundamentally addressing adipogenesis rather than just treating symptoms. The stem cells differentiate into adipocytes that resist lipid accumulation, providing a fundamental treatment mechanism that dietary and drug therapies cannot achieve.
2Reliability
If mesenchymal stem cells are used to inhibit adipogenesis, then fundamental treatment of fat accumulation is achieved, but the complexity of the therapeutic agent increases
Solution Approach 1:
The mesenchymal stem cells possess self-service capabilities through their inherent ability to self-differentiate into adipocytes that are resistant to lipid accumulation. The cells autonomously perform the therapeutic function without requiring complex external control systems or continuous intervention. This self-differentiation and self-regulation mechanism reduces the operational complexity despite the biological sophistication of the therapeutic agent.
3Ease of operation
If conventional therapies are used for fat accumulation, then treatment can be administered, but safety and effectiveness are insufficient
Solution Approach 1:
The patent fundamentally changes the therapeutic parameter from chemical interventions (dietary therapy and drug therapy) to biological cell-based therapy. By transitioning from small molecule drugs to living mesenchymal stem cells, the treatment achieves both ease of administration (through standard cell therapy routes) and enhanced safety-effectiveness profile (through the cells' selective differentiation into lipid-resistant adipocytes). This parameter change resolves the contradiction between administrability and reliability.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided is a composition for inhibiting, preventing, alleviating, or treating adipogenesis. Mesenchymal stem cells according to one aspect or a composition comprising the same inhibit fat accumulation or adipose tissue increase and thus may be advantageously utilized in the prevention, treatment, or alleviation of diseases associated with abnormal fat metabolism.